Share
Seeger Weiss partner Parvin Aminolroaya recently appeared on CBS News to discuss ongoing litigation against pharmaceutical companies Novo Nordisk and Eli Lilly over their popular GLP-1 receptor agonist medications such as Ozempic, Wegovy, Mounjaro, and Zepbound. Our firm represents patients across the country who allege they suffered serious medical complications while taking these drugs and did not receive adequate warnings about conditions such as gastroparesis, intestinal blockage and ileus. Parvin was appointed to serve as co-lead counsel earlier this year in the GLP-1 Receptor Agonists Products Liability Litigation.
The segment highlighted the story of Juanita Gantt, a firm client and plaintiff in the litigation, who suffered from ischemic bowel after taking Ozempic and Wegovy for diabetes and weight loss. After falling unconscious, Mrs. Gantt had to be rushed to the hospital where she nearly died due to her condition. Doctors were forced to remove her entire large intestine, leaving her dependent on an ileostomy bag.
“I had no warning that this was even a possibility,” she said.
Regarding the conduct of Novo Nordisk, Parvin said that the company has “put a lot of resources into marketing the drug, hundreds of millions of dollars to expand the market get new patients for the drug, but it hasn’t spent that money on warning patients of the risk of gastroparesis, ileus, small bowel obstruction, and the fact that these injuries can be severe.”
Mrs. Gantt’s life, like many other patients taking GLP-1s, has been permanently altered by her experience, causing significant emotional and physical suffering for her and her family.
The full segment can be viewed here. To learn more about Seeger Weiss’s representation of patients who took Ozempic and other GLP-1 drugs, click here.